Skip to content

A clinical randomized controlled study on electroacupuncture treatment for Parkinson's disease

A clinical randomized controlled study on electroacupuncture treatment for Parkinson's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002288
Enrollment
Unknown
Registered
2025-11-21
Start date
2025-11-27
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Experimental Group:Electroacupuncture

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Diagnosed with Parkinson's disease according to the 2015 International Parkinson and Movement Disorder Society (MDS) clinical diagnostic criteria for Parkinson's disease; (2) Aged 40-75 years, right-handed; (3) With a Hoehn-Yahr stage of 1-4; (4) In a relatively stable condition, with no change in medication dosage or no medication taken within the last 30 days; (5) Signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Severe cardiovascular and cerebrovascular diseases, liver or kidney diseases, malignant tumors, hematopoietic system diseases, or other life-threatening conditions; (2) History of alcohol or substance abuse, severe allergic constitution, severe mental disorders, or individuals with a cardiac pacemaker; (3) Pregnant or lactating women; (4) Individuals who have undergone Parkinson's disease-related surgical treatments (e.g., pallidotomy, deep brain stimulation, cervical deep venous lymph node anastomosis, etc.); (5) Participation in other clinical trials involving drugs, acupuncture, etc., within one month prior to inclusion in this study; (6) Inability to tolerate MRI or color Doppler ultrasound examinations; (7) Unsuitable for acupuncture due to reasons such as skin lesions at the operation site; (8) Inability to comply with the treatment protocol.

Design outcomes

Primary

MeasureTime frame
MDS-UPDRS;

Secondary

MeasureTime frame
PET-MRI;fMRI;DTI-ALPS;MSUS;TCS;Contrast-Enhanced Transcranial Ultrasound;Timed Up and Go Test;Patient Health Status Questionnaire-9;Parkinson's Disease Questionnaire - 8;Parkinson's Disease Sleep Scale;HAMD-17;

Countries

China

Contacts

Public ContactNing Baile

Guangdong Provincial Hospital of Chinese Medicine

ningbaile@163.com13824420916

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026